Browsing by Subject "Drug Discovery"
Now showing items 1-12 of 12
-
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).
(BMC Med, 2016-03-23)BACKGROUND: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed ... -
Chemical Biology Approaches to Interrogate Heat Shock Transcription Factor 1 Regulation in Cancer
(2020)Heat Shock transcription Factor 1 (HSF1) has long been recognized as the master regulator and signal integrator in the eukaryotic proteotoxic stress response. Revealed by recent discoveries in cancer, the functions of HSF1 ... -
Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents.
(Nature communications, 2019-09)Calcineurin is important for fungal virulence and a potential antifungal target, but compounds targeting calcineurin, such as FK506, are immunosuppressive. Here we report the crystal structures of calcineurin catalytic (CnA) ... -
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
(PLoS Pathog, 2014-05) -
Human endotoxin administration as an experimental model in drug development.
(Clin Pharmacol Ther, 2014-10)Linking human physiology to inflammatory mechanisms discovered in vitro or in animal models is essential to determine their importance. Innate immunity underlies many of these inflammatory responses in health and disease. ... -
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
(Cancer Prev Res (Phila), 2008-07)Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face significant scientific, regulatory, and economic barriers, however, ... -
Priorities for the Priority Review Voucher.
(Am J Trop Med Hyg, 2017-01-11)The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease ... -
Structure and Dynamics Based Methods Targeting RNA
(2019)As non-coding RNAs are increasingly implicated in cellular regulatory functions and disease states, there is a need to deepen our understanding of RNA structure-function relationships as well as to develop methods targeting ... -
Targeting the SUMO pathway for neuroprotection in brain ischaemia.
(Stroke and vascular neurology, 2016-09)Small ubiquitin-like modifier (SUMO) conjugation (SUMOylation) is a post-translational protein modification that modulates almost all major cellular processes, and has been implicated in many human diseases. A growing body ... -
The cost of drug development.
(N Engl J Med, 2015-05-14) -
Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury.
(Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020-04)Over the last few decades, increasing evidence demonstrates that the neuroinflammatory response is a double-edged sword. Although overly robust inflammatory responses may exacerbate secondary tissue injury, inflammatory ... -
Vaccines in 2017: Closing in on a Zika virus vaccine.
(Nature reviews. Immunology, 2018-02)
